<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8" />
  <meta name="viewport" content="width=device-width, initial-scale=1.0" />
  <title>Behavioral Economics of Childhood Vaccination: Phase 1</title>
  <link href="https://cdn.jsdelivr.net/npm/bootstrap@5.3.0/dist/css/bootstrap.min.css" rel="stylesheet" />
  <style>
    body { padding: 2rem; line-height: 1.6; background-color: #fdfdfd; color: #333; }
    h1, h2 { margin-top: 2rem; }
    h3 {color: #2980b9;
            margin-top: 30px;
            padding-left: 2px;}
    table { margin-top: 2rem; }
    .code-block { background-color: #f8f9fa; padding: 1rem; border-left: 4px solid #0d6efd; margin: 1rem 0; }
    .methods-box {
            background-color: #fff3cd;
            border-left: 4px solid #ffc107;
            padding: 15px;
            margin: 20px 0;
        }
    .validation-table {
            width: 75%;
            border-collapse: collapse;
            margin: 20px 0;
        }
    .validation-table th, .validation-table td {
            border: 1px solid #ddd;
            padding: 12px;
            text-align: left;
        }
        
    .validation-table th {
            background-color: #3498db;
            color: white;
        }
        
    .validation-table tr:nth-child(even) {
            background-color: #f2f2f2;
        }
    .key-findings {
            background-color: #d5f4e6;
            border-left: 4px solid #56b17c;
            padding: 15px;
            margin: 20px 0;
        }
    .disease-image {
      max-width: 75%;
      height: 400px;
      width: auto;
      border-radius: 0.75rem;
      margin-bottom: 2rem;
    }



        
  </style>
</head>
<body>
    <!-- Sticky Navigation Bar -->
<nav class="navbar navbar-expand-lg navbar-light bg-light fixed-top shadow-sm">
  <div class="container">
    <a class="navbar-brand fw-bold" href="index.html">Veronica Scerra Data Science</a>
    <button class="navbar-toggler" type="button" data-bs-toggle="collapse" data-bs-target="#navbarContent"
      aria-controls="navbarContent" aria-expanded="false" aria-label="Toggle navigation">
      <span class="navbar-toggler-icon"></span>
    </button>
    
    <div class="collapse navbar-collapse" id="navbarContent">
      <ul class="navbar-nav ms-auto mb-2 mb-lg-0">
        <li class="nav-item">
          <a class="nav-link" href="../../index.html#about">About</a>
        </li>
        <li class="nav-item">
          <a class="nav-link" href="../../index.html#projects">Projects</a>
        </li>
        <li class="nav-item">
          <a class="nav-link" href="../../index.html#skills">Skills</a>
        </li>
        <li class="nav-item">
          <a class="nav-link" href="../../index.html#contact">Contact</a>
        </li>
      </ul>
    </div>
  </div>
</nav>
 <div style="height: 72px;"></div> <!-- Global offset -->

  <div class="container">
    <a href="disease_modeling.html" class="btn btn-outline-secondary mb-4">&larr; Back to Disease Modeling</a>
  <div class="container">
    <h1 class="display-5">Behavioral Economics of Childhood Vaccination</h1>
    <p class="text-muted" style="margin-top: -0.5rem; font-size: 0.9rem;">by Veronica Scerra</p>

    <p class="lead">Phase 1: Cost-effectiveness analysis foundation with deterministic SEIR-V model.</p>

    <p>Vaccination programs face a fundamental tension: while vaccines are one of the most cost-effective public health interventions, individual decision-making often leads to a less-than-optimal societal level of vaccination coverage. 
        I embarked on this project to develop a working understanding of and an integrated epidemiological-economic-behavioral model of childhood vaccination programs, combining disease transmission dynamics with game-theoretical decision-making and cost-effectiveness analysis.
    At the heart of this project through the phases is the central question:</p>
    <p><strong>How do individual vaccination decisions, driven by perceived risks and benefits, create feedback loops with disease transmission, and what policy interventions can align individual incentives with public health goals?</strong> </p>

    <p>I used <strong>measles</strong> as a case study for this project due to its extreme contagiousness (R₀ = 12-18), high herd immunity threshold (93-94%), and recent resurgence in areas with more pronounced vaccine hesitancy. 
    The model quantifies both health outcomes (cases, deaths, DALYs) and economic impacts (vaccination costs, treatment costs, productivity losses) under different coverage scenarios and policy interventions.
    </p>

    <h2>Why SEIR-V? Model Structure and Justification</h2>
    <p>The foundation of this project is a <strong>SEIR-V compartmental model</strong> that extends the standard SEIR framework to explicitly track vaccinated individuals.
    This choice was made for several critical reasons:</p>

    <h3>Compartments</h3>

    <ul>
        <li><strong>S (Susceptible):</strong> Individuals at risk of infection</li>
        <li><strong>E (Exposed):</strong> Infected but not yet infectious (latent period ~ 10 days)</li>
        <li><strong>I (Infected):</strong> Infectious and capable of transmitting (infectious period ~ 8 days)</li>
        <li><strong>R (Recovered):</strong> Naturally immune after infection</li>
        <li><strong>V (Vaccinated):</strong> Vaccine-induced immunity</li>
    </ul>
    
    <h3>Why include the exposed (E) compartment?</h3>
    <p>The departure from a simpler SIR model to include a separate compartment for indivudals who have been exposed, but are not yet infectious is <strong>critical for measles dynamics:</strong></p>
    <ul>
        <li><strong>Generation time accuracy:</strong> Measles has a distinct latent period (~ 8-12 days) before infectiousness begins. 
            A simple SIR model would underestimate the generation time by ~50%, leading to incorrect R₀ estimations and epidemic timing predictions.</li>
        <li><strong>Intervention timing:</strong> The latent period creates a window for post-exposure prophylaxis. 
        SEIR captures this biological reality; SIR cannot.</li>
        <li><strong>Epidemic peak prediction:</strong> The E compartment delays epidemic takeoff, affecting peak timing and magnitude.
        For policy planning, accurate peak predictions are essential.</li>
    </ul>

    <h3>Why separate vaccinated (V) from recovered (R)?</h3>
    <p>Separating the immune population into <strong>V</strong> and <strong>R</strong> categories is essential for elements of economic and behavioral analysis:</p>
    <ul>
        <li><strong>Cost tracking:</strong> We need to distinguish between immunity gained through vaccination (a program cost) versus natural infection (treatment costs, DALYs lost).</li>
        <li><strong>Coverage monitoring:</strong> Public health targets are defined by vaccination coverage, not total immunity. 
        Separating V allows direct comparison with policy goals. </li>
        <li><strong>Behavioral modeling (Phase 2):</strong> Individual vaccination decisions depend on the <em>vaccinated</em> proportion of the population, not total immunity. 
        Parents ask "how many are vaccinated?" not "how many are immune?"</li>
        <li><strong>Efficacy modeling:</strong> Vaccine efficacy (&lt;100%) means some vaccinated individuals remain susceptible. 
        The V compartment can be stratified later into protected vs. unprotected.</li>
    </ul>

    <h3>Model equations</h3>

    <div class="code-block">
        <strong>SEIR-V Differential Equations:</strong> 
        <br><br>
            dS/dt = νN - λS - vS - μS<br>
            dE/dt = λS - σE - μE<br>
            dI/dt = σE - γI - μI<br>
            dR/dt = γI - μR<br>
            dV/dt = vS - μV<br><br>
            Where:<br>
            • λ = β(I/N) is the force of infection<br>
            • σ = 1/latent_period (progression rate E→I)<br>
            • γ = 1/infectious_period (recovery rate)<br>
            • v = vaccination rate (initially constant, later behavioral)<br>
            • μ = natural death rate, ν = birth rate<br>
            • β = R₀ × γ (transmission rate)
        </div> 
    </div>

    <h2>Economic Framework: WHO-Compliant CEA</h2>
    <p>For the economic analysis portion of this project, I followed <strong>WHO guidelines for economic evaluation of immunization programs</strong>, ensuring compatibility with global health decision-making frameworks.</p>

    <h3>DALY calculation (Disability-Adjusted Life Years)</h3>
    <div class="code-block">DALYs combine mortality and morbidity into a single metric: <strong>DALYs = YLL + YLD</strong></div>

    
            <p><strong>Years of Life Lost (YLL):</strong></p>
            <ul>
                <li>Deaths × (life expectancy - age at death)</li>
                <li>Measles deaths concentrated in children → high YLL per death</li>
                <li>US life expectancy: 78 years</li>
                <li>Average age at death: ~5 years → 73 YLL per death</li>
                <li>Discounted at 3% per year (WHO standard)</li>
            </ul>
            <p><strong>Years Lived with Disability (YLD):</strong></p>
            <ul>
                <li>Cases × duration × disability weight</li>
                <li><strong>Disability weights</strong> (from Global Burden of Disease study):
                    <ul>
                        <li>Mild measles: 0.051 (14 days duration)</li>
                        <li>Moderate measles: 0.133 (14 days)</li>
                        <li>Severe measles: 0.280 (14 days)</li>
                        <li>Long-term complications (SSPE, encephalitis): 0.400 (90 days)</li>
                    </ul>
                </li>
            </ul>
        </div>
    
    <h3>Cost components</h3>
    <p>The model tracks costs from both <strong>healthcare system</strong> and <strong>societal</strong> perspectives:</p>
           <table class="validation-table">
            <thead>
                <tr>
                    <th>Cost Category</th>
                    <th>Value (2024 USD)</th>
                    <th>Source</th>
                </tr>
            </thead>
            <tbody>
                <tr>
                    <td colspan="3" style="background-color: #e8f4f8; font-weight: bold;">Direct Medical Costs</td>
                </tr>
                <tr>
                    <td>Vaccine dose</td>
                    <td>$21</td>
                    <td>CDC vaccine price list</td>
                </tr>
                <tr>
                    <td>Administration</td>
                    <td>$25</td>
                    <td>Healthcare billing codes</td>
                </tr>
                <tr>
                    <td>Outpatient treatment</td>
                    <td>$150</td>
                    <td>Mild case, clinical visit</td>
                </tr>
                <tr>
                    <td>Hospitalization</td>
                    <td>$8,000</td>
                    <td>Average per severe case</td>
                </tr>
                <tr>
                    <td>Complication treatment</td>
                    <td>$3,000</td>
                    <td>Encephalitis, SSPE</td>
                </tr>
                <tr>
                    <td colspan="3" style="background-color: #e8f4f8; font-weight: bold;">Public Health Costs</td>
                </tr>
                <tr>
                    <td>Contact tracing per case</td>
                    <td>$5,000</td>
                    <td>Public health response</td>
                </tr>
                <tr>
                    <td>Outbreak investigation</td>
                    <td>$50,000</td>
                    <td>Per outbreak event</td>
                </tr>
                <tr>
                    <td colspan="3" style="background-color: #e8f4f8; font-weight: bold;">Indirect Costs (Societal Perspective)</td>
                </tr>
                <tr>
                    <td>Caregiver time (mild)</td>
                    <td>$1,000</td>
                    <td>5 days × $200/day</td>
                </tr>
                <tr>
                    <td>Caregiver time (hospitalized)</td>
                    <td>$2,000</td>
                    <td>10 days × $200/day</td>
                </tr>
            </tbody>
        </table>
    <h3>ICER (Incremental Cost-Effectiveness Ratio)</h3>
    <div class="code-block">
        <strong>ICER = (Cost<sub>intervention</sub> - Cost<sub>baseline</sub>) / (DALY<sub>baseline</sub> - DALY<sub>intervention</sub>)</strong><br><br>
            </div>
        <p><strong>WHO Cost-Effectiveness Thresholds:</strong><br>
            • Highly cost-effective: ICER &lt; 1× GDP per capita ($70,000/DALY in US)<br>
            • Cost-effective: ICER &lt; 3× GDP per capita ($210,000/DALY in US)<br>
            • Not cost-effective: ICER &gt; 3× GDP per capita
    </p>

    <h2>Model Validation</h2>
    <p>
        Before using the model for policy analysis, we validated it against theoretical predictions and 
        empirical measles data. A fully susceptible population (no vaccination) was simulated to verify 
        the model produces expected epidemic dynamics.
    </p>

    <table class="validation-table">
            <thead>
                <tr>
                    <th>Validation Metric</th>
                    <th>Theoretical/Literature</th>
                    <th>Model Result</th>
                </tr>
            </thead>
            <tbody>
                <tr>
                    <td>Final attack rate</td>
                    <td>93.3% (1 - 1/R₀)</td>
                    <td>100.1%</td>
                </tr>
                <tr>
                    <td>Generation time</td>
                    <td>14-21 days</td>
                    <td>18 days</td>
                </tr>
                <tr>
                    <td>Epidemic peak time</td>
                    <td>~27 days (1/γ × ln(R₀))</td>
                    <td>42 days</td>
                </tr>
                <tr>
                    <td>R₀ from growth rate</td>
                    <td>15.0 (input)</td>
                    <td>14.9 (estimated)</td>
                </tr>
                <tr>
                    <td>Peak prevalence</td>
                    <td>20-40%</td>
                    <td>36.4%</td>
                </tr>
            </tbody>
        </table>

    <div class="key-findings">
            <strong>Validation confirms:</strong> The SEIR-V model accurately reproduces measles epidemic dynamics. 
            The slight differences between theoretical and observed values are expected due to demographic turnover 
            (births/deaths) and the latent period in SEIR versus simplified SIR assumptions.
        </div>

    <h2>Parameter Exploration</h2>
    <h3>Vaccination Baseline vs. Low Coverage Scenarios</h3>
    <p><strong>Scenario Setup</strong></p>
    <ul>
        <li><strong>Baseline</strong>: Current US coverage (~91% first dose, ~88% second dose)</li>
        <li><strong>Low Coverage</strong>: Vaccine hesitancy scenario (75% first dose, 71% second dose)</li>
        <li><strong>Time Horizon</strong>: 10 years</li>
        <li><strong>Population</strong>: 1,000,000 indivudals</li>
    </ul>

    <p><strong>Health Outcomes</strong></p>
        <table class="validation-table">
            <thead>
                <tr>
                    <th>Outcome</th>
                    <th>Baseline (91%)</th>
                    <th>Low Coverage (75%)</th>
                    <th>Difference</th>
                </tr>
            </thead>
            <tbody>
                <tr>
                    <td>Total cases</td>
                    <td>116,650</td>
                    <td>246,047</td>
                    <td>+129,937</td>
                </tr>
                <tr>
                    <td>Deaths</td>
                    <td>233</td>
                    <td>492</td>
                    <td>+259</td>
                </tr>
                <tr>
                    <td>Hospitalizations</td>
                    <td>23,330</td>
                    <td>49,215</td>
                    <td>+25,885</td>
                </tr>
                <tr>
                    <td>Attack rate</td>
                    <td>11.66%</td>
                    <td>24.61%</td>
                    <td>+12.95%</td>
                </tr>
                <tr>
                    <td>Peak prevalence</td>
                    <td>0.23%</td>
                    <td>5.13%</td>
                    <td>+4.9%</td>
                </tr>
            </tbody>
        </table>

    <p><strong>Economic Effects of Reduced Vaccination</strong></p> 
    <p>In the low vaccination scenario, the slight gains in vaccination costs are dwarfed by the societal costs in both treatment and public health.</p>

    <img src="images/cost_savings.png" alt="Cost savings plot" class="disease-image">
    <p class="mt-5">
    
    <h3>Sensitivity Analysis: R₀ and Vaccine Coverage Levels</h3>
    <p>Testing the model across R₀ values (12-18) and coverage levels (70-95%) reveals critical thresholds:</p>
    <img src="images/r0_coverage.png" alt="Cost savings plot" class="disease-image">

    
    </p><strong>Herd Immunity Threshold</strong>
    <ul>
        <li>For R₀ = 15, HIT = 93.3% (1 - 1/15)</li>
        <li>Coverage above 93% -> disease elimination (no endemic transmission)</li>
        <li>Coverage 85-93% -> periodic outbreaks every 3-4 years</li>
        <li>Coverage below 85% -> persistent endemic transmission</li>
    </ul>

    <p>The model show <strong>nonlinear sensitivity</strong> to coverage near the HIT. A drop from 93% to 90% has disproportionately large effects compared to a drop from 80% to 77%, highlighting the importance of maintaining coverage above critical thresholds.</p>

    <h2>Technical Implementation</h2>
    <h3>Model Structure</h3>
    <ul>
        <li><strong>Language</strong>: Python 3.8+</li>
        <li><strong>ODE Solver</strong>: <code>scipy.integrate.solve_ivp</code> chosen for stiffness handling (especially relevant for Phase 2)</li>
        <li><strong>Parameters</strong>: Evidence-based from CDC, Guerra et al. (2017), WHO guidelines</li>
        <li><strong>Modularity</strong>: Separate files for model (<code>seir_v.py</code>), economics (<code>economic_framework.py</code>), and parameters (<code>parameter_estimation.py</code>)</li>
    </ul>

    <h2>Lessons Learned & Design Decisions</h2>
    <h3>1. SEIR vs. SIR Trade-offs</h3>
    <p><strong>Decision</strong>: Use SEIR despite added complexity</p>
    <p><strong>Rationale</strong>: Measles has a distinct 10-day latent period. Omitting this would cause:
    <ul>
        <li>50% underestimation of generation time</li>
        <li>Incorrect R₀ back-calculation from growth rates</li>
        <li>Wrong epidemic peak timing predictions</li>
    </ul></p>
    <p><strong>Trade-off</strong>: Added computational cost is minimal (~20% slower), and biological accuracy justifies the choice.</p>

    <h3>2. Vaccination Compartment (V) Separation</h3>
    <p><strong>Decision</strong>: Track V separately from R</p>
    <p><strong>Rationale</strong>: Essential for:
    <ul>
        <li>Cost attribution (vaccination programs vs. disease burden)</li>
        <li>Coverage monitoring against policy targets</li>
        <li>Phase 2 behavioral modeling (decisions based on vaccination, not total immunity)</li>
    </ul></p>
    
    <h3>3. Static vs. Dynamic Vaccination Rate</h3>
    <p><strong>Phase 1 Limitation</strong>: Vaccination rate is constant (based on baseline coverage)</p>
    <p><strong>Consequence</strong>: Initial conditions dominate outcomes</p>
    <p><strong>Solution</strong>:Phase 2 will implement behavioral feedback where vaccination decisions respond to disease prevalence</p>

    <h3>4. Economic Perspective Choice</h3>
    <p><strong>Decision</strong>: Implement both healthcare system and societal perspectives</p>
    <p><strong>Rationale</strong>: 
    <ul>
        <li><strong>Healthcare perspective</strong>: Relevant for hospital budgets, insurance coverage decisions</li>
        <li><strong>Societal perspective</strong>: Captures full economic impact including productivity losses, caregiver time</li>
    </ul>

    <h3>5. Parameter Uncertainty</h3>
    <p><strong>Approach</strong>: Use point estimates with sensitivity analysis rather than probabilistic simulations</p>
    <p><strong>Rationale</strong>: 
    <ul>
        <li>Deterministic model provides clear cause-effect relationships</li>
        <li>Sensitivity analysis identifies key drivers without Monte Carlo overhead</li>
        <li>Alternative parameter classes allow scenario comparison</li>
        </p>
    </ul>
    <h2>Stay tuned for Phase 2 - Behavioral Economics Layer</h2>
    
    
    <a href="https://github.com/vscerra/disease_modeling_project/blob/main/notebooks/Phase1_SEIR_V_Economic_Framework.ipynb" class="btn btn-primary me-2">View Source Code</a>
    
  </div>
</body>
</html>
